Montelukast sodium is under clinical development by IntelGenx and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Montelukast sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Montelukast sodium overview
Montelukast sodium (INT-0043) is under development for the treatment of mild cognitive impairment and Alzheimer's disease and Parkinson's disease. It is administered through buccal route. It is developed based on an immediate release oral film technology, VersaFilm. This technology utilizes a strip of thin polymeric film, which instantly releases the drug candidate.
See Also:
IntelGenx overview
IntelGenx is a Canadian oral drug delivery company. It develops pharmaceutical oral films based on its proprietary technology platform, VersaFilm.
For a complete picture of Montelukast sodium’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.